Xeltis

Healthtech · Eindhoven, NL

Clinical-stage medtech making restorative polymer vascular grafts and heart valves.

Founders

Martijn Cox (Netherlands · ♂) — After a PhD in cardiovascular tissue engineering at TU Eindhoven, he co-founded the spin-off QTIS/e, which merged into Xeltis where he became CTO developing restorative, self-regenerating heart valves and blood vessels.

Shares the most investors with (number = shared investors):

Date	Round	Amount
Jul 2026	Funding round Dutch and US MedTech company Xeltis raised an additional 20.5 million euros led by new investor Horizon 3 Healthcare to fund its US pivotal trial and European commercial rollout of its aXess vascular access implant.	$23.6M
Aug 2023	Funding round Eindhoven-based medtech Xeltis secured EUR12.5M from the European Innovation Council Fund for its restorative implants.	$13.4M
Feb 2023	Series D Plus Xeltis raised a EUR32M Series D2 from Grand Pharma, DaVita Venture Group, EQT Life Sciences and Invest-NL for its restorative cardiovascular implants.	$32M
Aug 2022	Series D Plus Dutch medtech Xeltis raised a 15M euro Series D2 from China's Grand Pharmaceutical Group, focused on its aXess hemodialysis access device.	$15M
Nov 2021	Debt Swiss-Dutch medtech Xeltis secured EUR 15M in quasi-equity financing from the European Investment Bank to advance its restorative cardiovascular devices.	$17.7M

Tap an investor to see what else they have backed.

Data is community-curated and may be incomplete.